The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Expanding immunotherapy options in cholangiocarcinoma: Role of CD27 agonist in combination with PD-L1 and MEK inhibition on antitumor effect and CD8+ T cells.
 
Frances Jenkins Bennett
No Relationships to Disclose
 
Emilie AK Warren
No Relationships to Disclose
 
Jacklyn Hammons
No Relationships to Disclose
 
Megen Wittling
No Relationships to Disclose
 
Megan Wyatt
Patents, Royalties, Other Intellectual Property - Pending Patent PCT/US2022/051528: Ex Vivo Cytokine Priming Strategies For Preparing Activated CD26-High Immune Cells And Uses In Cancer Therapies
 
Guillermo Omar Rangel Rivera
Patents, Royalties, Other Intellectual Property - Emory University
 
Nilofer Saba Azad
Stock and Other Ownership Interests - Haystack Oncology
Consulting or Advisory Role - AstraZeneca; Helsinn Therapeutics/QED Therapeutics; Incyte; Jazz Pharmaceuticals; Jazz Pharmaceuticals; Merck; Mirati Therapeutics; QED Therapeutics; Taiho Pharmaceutical; Tempus
Speakers' Bureau - AstraZeneca
Research Funding - Agios (Inst); Array BioPharma (Inst); Astex Pharmaceuticals (Inst); AtlasMedx (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Debiopharm Group (Inst); EMD Serono (Inst); Genentech (Inst); Incyte (Inst); Intensity Therapeutics (Inst); Loxo/Lilly (Inst); Merck (Inst); Mirati Therapeutics (Inst); Syndax (Inst)
Travel, Accommodations, Expenses - Mirati Therapeutics
 
Mark Yarchoan
Leadership - Adventris Pharmaceuticals
Stock and Other Ownership Interests - Adventris Pharmaceuticals
Consulting or Advisory Role - AstraZeneca; Eisai; Exelixis; Genentech/Roche; Hepion Pharmaceuticals; Replimune
Research Funding - Bristol-Myers Squibb (Inst); Exelixis (Inst); Incyte (Inst); Merck (Inst)
(OPTIONAL) Uncompensated Relationships - Merck
 
Thatcher Ross Heumann
Honoraria - American Journal of Managed Care; Primum; Total Health
Consulting or Advisory Role - AstraZeneca; Eisai; Elevance Health; Primum
Travel, Accommodations, Expenses - Eisai
 
Tibor Keler
Employment - Celldex
Leadership - Celldex
Travel, Accommodations, Expenses - Celldex
 
Shishir K. Maithel
Consulting or Advisory Role - AstraZeneca
Research Funding - Celgene
 
Chrystal M Paulos
Leadership - Ares Immunotherapy
Stock and Other Ownership Interests - Ares Immunotherapy
Consulting or Advisory Role - Ares Immunotherapy
Research Funding - Biolocity
Patents, Royalties, Other Intellectual Property - Have patents and patents pending
(OPTIONAL) Uncompensated Relationships - Ares Immunotherapy
 
Gregory B. Lesinski
Research Funding - Boehringer Ingelheim; Bristol-Myers Squibb; Merck; Vaccinex